Calendar

Biomarkers

Biomarkers

Currently, the diagnosis of neurodegenerative diseases is mainly based on clinical criteria that allow a ‘probability’ diagnostic approach, once other causes have been ruled out. Accurate diagnosis of the disease is only achieved in post-mortem studies.

Research into neurodegenerative diseases has made significant strides in recent years towards more accurate and accessible diagnosis. Among the most promising developments are new techniques for the detection of pre-mortem biomarkers capable of accurately diagnosing the disease.

These innovative methodologies surpass traditional immunoassays in accuracy, allowing for more sensitive and reliable measurements. Moreover, compared to procedures such as cerebrospinal fluid (CSF) analysis and positron emission tomography (PET), blood-based tests offer a more scalable, less invasive alternative with remarkably efficient clinical potential.

These advances open the door to earlier and more accessible diagnostics, favouring the timely initiation of treatments to slow disease progression and improve patients' quality of life.

The Biomarkers / Biochemistry and Molecular Genetics Platform of CIEN arises from the need to search for biochemical markers of neurodegenerative diseases such as Alzheimer's not only in sick patients, but also to identify cases of incipient Alzheimer's in asymptomatic patients or those with mild cognitive impairment (MCI), so that specific treatments can be initiated to stop neurodegeneration before it becomes irreversible.

Furthermore, the Platform is part of a multidisciplinary environment that includes basic researchers, clinicians, neuropathologists and neuro-radiologists, thus favouring a diverse flow of information that will be of great help in the validation of potential markers of the disease.

biomarcadores
bioquimica
Working group
Aitana Sogorb Esteve

PhD in Neuroscience. Bachelor’s degree in Biology.

Principal Investigator and head of the platform.

Ana Belén Pastor

Senior technician in clinical and biomedical diagnostics laboratories

Sonia Wagner Reguero

PhD in Biology (Industrial Biology) | BSc in Biochemistry | Postdoctoral Researcher

Minerva Martínez

Graduate in Biochemistry, specialist in Neuropsychopharmacology.

Xayide Rodríguez Martínez

Advanced Technician in Clinical and Biomedical Diagnostic Laboratory

Andrea Ruiz Calvo

PhD in Neurosciences | Bachelor’s degree in Biology.

Michelle Guamán

Graduate in Biology, specialist in Neurosciences

Lines of research

Search for peripheral biomarkers in biological fluids such as blood, cerebrospinal fluid (CSF) and saliva using ultra-sensitivity technology, including:

  • SIMOA (Single Molecule Array): Enables the detection of biomarkers at extremely low concentrations with high precision, ideal for early diagnosis of neurodegenerative diseases.
  • Fujirebio: Specialises in automated immunoassays for the measurement of key biomarkers used in the diagnosis of Alzheimer's disease.
  • Olink: We have data from our biological samples obtained using this high sensitivity and specificity proteomics technology that allows the simultaneous detection of multiple biomarkers in biological samples with minimal volumes. Designed to analyse key proteins involved in processes such as neuroinflammation, synaptic dysfunction and protein aggregation, essential factors in diseases such as Alzheimer's, Parkinson's and ALS, we have data on around 2,900 proteins. Thanks to its approach based on Proximity Extension Assay (PEA) technology, Olink offers accurate and reproducible quantification, facilitating the identification of new therapeutic targets and the search for biomarkers for the diagnosis and monitoring of neurodegenerative diseases. These technologies stand out for their ability to improve sensitivity and specificity in the detection of biomarkers, facilitating earlier and more accessible diagnosis for various neurodegenerative pathologies.

*RT Quic (Real-Time Quaking-Induced Conversion): is an innovative tool used to detect the presence of misfolded proteins, such as alpha-synuclein and tau, associated with neurodegenerative diseases. Its non-invasive nature, using biological fluids such as CSF or blood, and its ability to accurately identify pathological changes make it a promising tool for research and clinical diagnosis.

*Extracellular particles (EVs): play a crucial role in intercellular communication and have emerged as biomarkers and potential mediators in neurodegenerative diseases. These nanometric structures, released by various cell types, transport proteins, lipids and genetic material, modulating neuronal homeostasis and inflammatory response. In pathologies such as Alzheimer's disease, Parkinson's disease and ALS, EVs may facilitate the propagation of misfolded proteins, contributing to neurodegeneration. They also possess neuroprotective properties by removing toxic aggregates and regulating the immune response. Their study opens up new opportunities for the development of innovative diagnostic and therapeutic strategies in neurology.

*Searching for genetic susceptibility factors to understand predisposition to various diseases, including neurodegenerative diseases. These findings not only improve knowledge of the underlying molecular mechanisms, but may also contribute to the development of early diagnostic tools and personalised medicine strategies, allowing more effective interventions tailored to the individual genetics of each patient, based on precision medicine.

*DNA and biological samples biobank, a key infrastructure for research in neurosciences and other biomedical areas. Our biobank has:

  • DNA biobank: Collection of high quality samples for genetic and biomarker studies.
  • Biobank of biological samples: Includes blood, cerebrospinal fluid (CSF), saliva, tears and hair, allowing a multidimensional approach to disease research.

Our biobank is a key resource for advancing our understanding of the molecular mechanisms of disease and the development of new diagnostic and therapeutic strategies.

*Research platform for external groups: we offer access to our samples and data under strict ethical and quality protocols, facilitating collaboration with other national and international research groups.

* External service for the use of SIMOA, Fujirebio and Real Time - PCR (coming soon): We offer a specialised service for research groups and companies that require the use of advanced technologies in biomarkers and molecular analysis. We have state-of-the-art platforms such as SIMOA (Single Molecule Array), which allows the ultra-sensitive detection of proteins in biological fluids; Fujirebio, recognised for its high precision in the analysis of neurodegenerative biomarkers through automated assays; and Real Time-PCR, ideal for the quantification of nucleic acids in gene expression studies and molecular diagnostics. Our team offers technical support and advice to optimise the use of these technologies in biomedical research projects.

Featured Publications
  • Bolsewig K, Willemse EAJ, Sánchez-Juan P, Rábano A, Martínez M, Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, Mattsson-Carlgren N, Veverova K, Fowler CJ, Boonkamp L, Koel-Simmelink M, Hussainali Z, Ruiters DN, Gaetani L, Toja A, Fortea J, Pijnenburg Y, Lemstra AW, van der Flier WM, Hort J, Otto M, Hansson O, Parnetti L, Masters CL, Lleó A, Teunissen CE, Del Campo Milán M.

    Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.

    Nat Commun. 2025 Jan 29;16(1):1139. doi:10.1038/s41467-025-56293-z. PMID: 39881147.

    Examines plasma DOPA decarboxylase levels in Lewy body disorders and shows that their increase is related to dopaminergic treatment, which limits its usefulness as a diagnostic biomarker.
    View publication
  • Gómez-Tortosa E, Agüero-Rabes P, Ruiz-González A, Wagner-Reguero S, Téllez R, Mahillo I, Ruiz-Calvo A, Sainz MJ, Nystrom AL, Del Ser T, Sánchez-Juan P.

    Plasma Biomarkers in the Distinction of Alzheimer's Disease and Frontotemporal Dementia.

    Int J Mol Sci. 2025 Jan 30;26(3):1231. doi:10.3390/ijms26031231. PMID: 39940998.

    Analyzes the usefulness of plasma biomarkers for differentiating Alzheimer's disease from frontotemporal dementia, contributing to the development of less invasive diagnostic tools.
    View publication
  • Gómez-Tortosa E, Agüero-Rabes P, Ruiz-González A, Wagner S, Téllez R, Mahillo I, Ruiz-Calvo A, Sainz MJ, Nystrom AL, Cremades-Jimeno L, Del Ser T, Sánchez-Juan P.

    Plasma Neurodegenerative Biomarkers in Cognitively Preserved Nonagenarians.

    Aging Dis. 2025;16(5):3128-3136. doi:10.14336/AD.2024.1260. PMID: 39571163.

    Studies plasma neurodegenerative biomarkers in nonagenarians with preserved cognitive function, providing insight into the mechanisms associated with healthy aging.
    View publication
  • Sánchez-Juan P, Valeriano-Lorenzo E, Ruiz-González A, Pastor AB, Rodrigo Lara H, López-González F, Zea-Sevilla MA, Valentí M, Frades B, Ruiz P, Saiz L, Burgueño-García I, Calero M, Del Ser T, Rábano A.

    Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles.

    Brain. 2024 May 3;147(5):1667-1679. doi:10.1093/brain/awae035. PMID: 38634687.

    Analyzes the relationship between serum GFAP levels, astrocyte reactivity, brain atrophy and neurofibrillary tangle burden. The results support its potential as a biomarker of neurodegenerative pathology and of Alzheimer's disease progression.
    View publication
  • García-Alberca JM, de Rojas I, Sanchez-Mejias E, Garrido-Martín D, Gonzalez-Palma L, Jimenez S, Pino-Angeles A, Cruz-Gamero JM, Mendoza S, Alarcón-Martín E, et al.

    An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response.

    J Alzheimers Dis. 2024;98(2):601-618. doi:10.3233/JAD-231150. PMID: 38427484.

    Studies the effect of a genetic variant in SIRPβ1 on the microglial response and the course of Alzheimer's disease. The results show differential effects on the risk of progression from mild cognitive impairment to dementia and on the rate of cognitive decline.
    View publication
  • Botello-Marabotto M, Martínez-Bisbal MC, Calero M, Bernardos A, Pastor AB, Medina M, Martínez-Máñez R.

    Non-invasive biomarkers for mild cognitive impairment and Alzheimer's disease.

    Neurobiol Dis. 2023 Oct 15;187:106312. doi:10.1016/j.nbd.2023.106312. PMID: 37769747.

    Explores the potential of metabolomics using nuclear magnetic resonance spectroscopy (¹H NMR) in serum samples to identify non-invasive biomarkers of mild cognitive impairment and Alzheimer's disease.
    View publication
  • Gómez-Tortosa E, Baradaran-Heravi Y, Dillen L, Roy Choudhury N, Agüero-Rabes P, Pérez-Pérez J, Kocoglu C, Sainz MJ, Ruiz-González A, Téllez R, Cremades-Jimeno L, Cárdaba B, EU EOD Consortium, Van Broeckhoven C, Michlewski G, van der Zee J.

    TRIM25 mutation (p.C168*), coding for an E3 ubiquitin ligase, is a cause of early-onset autosomal dominant dementia with amyloid load and parkinsonism.

    Alzheimers Dement. 2023 Jul;19(7):2805-2815. doi:10.1002/alz.12913. Epub 2022 Dec 28. PMID: 36576960.

    Describes the identification of a mutation in the TRIM25 gene associated with a form of early-onset autosomal dominant dementia, characterized by amyloid accumulation and parkinsonism. The study proposes a new pathophysiological mechanism related to the loss of function of an E3 ubiquitin ligase.
    View publication